Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy

Journal of Infectious Diseases

Volumn 174, Issue 4, 1996, Pages 696-703

  Welles, S L ^a   Jackson, J B ^b   Yen Lieberman, B ^b   Demeter, L ^b   Japour, A J ^b   Smeaton, L M ^b   Johnson, V A ^b   Kuritzkes, D R ^b   D'Aquila, R T ^b   Reichelderfer, P A ^b   Richman, D D ^b   Reichman, R ^b   Fischl, M ^b   Dolin, R ^b   Coombs, R W ^b   Kahn, J O ^b   McLaren, C ^b   Todd, J ^b   Kwok, S ^b   Crumpacker, C S ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; CD4 ANTIGEN; RNA DIRECTED DNA POLYMERASE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 19244363449     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.4.696     Document Type: Article

References (13)

1. Holodniy M, Katzenstein DA, Sengupta S, et al. Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. J Infect Dis 1991;163:117-22.
2. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfiled L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994;32:292-300.
3. Pachl C, Todd JA, Kern DG et al. Rapid and precise quantitation of HIV-1 RNA in plasma using a branched DNA (bDNA) signal amplification assay. J Acquir Immune Defic Syndr 1995;8:446-54.
4. Semple M, Loveday C, Weller I, Redder R. Direct measurement of viremia in patients infected with HIV-1 and its relationship to disease progression and zidovudine therapy. J Med Virol 1991;35:38-45.
5. Piatak M, Saag MS, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993;259:1749-54.
6. Katzenstein DA, Winters M, Bubp J, Israelski D, Winger E, Merigan TC. Quantitation of human immunodeficiency virus by culture and polymerase chain reaction in response to didanosine after long-term therapy with zidovudine. J Infect Dis 1994;169:416-9.
7. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995;332:209-16.
8. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic, characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995;332:201-8.
9. Mellors JW, Kingsley LA, Rinaldo CR Jr, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573-9.
10. Boucher CA, Lange JM, Miedema FF, et al. HIV-I biologic phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS 1992; 6:1259-64.
11. Tudor-Williams G, St Clair MH, McKinney RE, et al. HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet 1992;339: 15-9.
12. St Clair MH, Hartigan PM, Andrews JC, Vavro CL, Simberkoff MS, Hamilton JD. Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. The VA Cooperative Study Group. J Acquir Immune Defic Syndr 1993;6:891-7.
13. Kozal MJ, Shafer R, Winters MA, Katzenstein DA, Merigan TC. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis 1993;167:526-32.